CHMP gives nod to GSK's Revolade
This article was originally published in Scrip
Executive Summary
The EU's CHMP has supported the approval of GlaxoSmithKline's novel treatment for chronic idiopathic thrombocytopenic purpura (ITP) Revolade (eltrombopag 25mg and 50mg, film-coated tablets) in patients who have had their spleen removed, and who do not respond to other treatments, such as corticosteroids and immunoglobulin therapies.